Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ERAS |
---|---|---|
09:32 ET | 10317 | 2.31 |
09:34 ET | 200 | 2.31 |
09:36 ET | 1628 | 2.3 |
09:38 ET | 3039 | 2.29 |
09:39 ET | 141 | 2.274 |
09:41 ET | 1050 | 2.2821 |
09:43 ET | 1100 | 2.29 |
09:48 ET | 100 | 2.275 |
09:50 ET | 300 | 2.28 |
09:52 ET | 28967 | 2.24 |
09:54 ET | 1675 | 2.22 |
09:56 ET | 7782 | 2.21 |
09:57 ET | 20219 | 2.195 |
09:59 ET | 10700 | 2.195 |
10:01 ET | 14240 | 2.215 |
10:03 ET | 2500 | 2.215 |
10:06 ET | 800 | 2.215 |
10:08 ET | 5934 | 2.24 |
10:10 ET | 600 | 2.24 |
10:12 ET | 884 | 2.25 |
10:14 ET | 10282 | 2.28 |
10:15 ET | 6388 | 2.285 |
10:17 ET | 2850 | 2.29 |
10:19 ET | 35487 | 2.265 |
10:21 ET | 17865 | 2.27 |
10:24 ET | 100 | 2.26 |
10:26 ET | 600 | 2.275 |
10:28 ET | 2000 | 2.27 |
10:30 ET | 300 | 2.27 |
10:32 ET | 2299 | 2.265 |
10:33 ET | 400 | 2.27 |
10:35 ET | 458 | 2.27 |
10:37 ET | 1200 | 2.27 |
10:39 ET | 600 | 2.27 |
10:42 ET | 600 | 2.265 |
10:44 ET | 20983 | 2.255 |
10:50 ET | 1100 | 2.26 |
10:51 ET | 1298 | 2.26 |
10:53 ET | 400 | 2.255 |
10:55 ET | 300 | 2.255 |
10:57 ET | 7379 | 2.25 |
11:00 ET | 6178 | 2.25 |
11:02 ET | 14904 | 2.255 |
11:08 ET | 6641 | 2.24 |
11:09 ET | 500 | 2.245 |
11:11 ET | 5946 | 2.25 |
11:13 ET | 900 | 2.255 |
11:15 ET | 703 | 2.26 |
11:18 ET | 300 | 2.26 |
11:20 ET | 418 | 2.26 |
11:22 ET | 1300 | 2.26 |
11:24 ET | 1100 | 2.26 |
11:26 ET | 200 | 2.26 |
11:27 ET | 1648 | 2.26 |
11:29 ET | 400 | 2.26 |
11:31 ET | 7656 | 2.25 |
11:33 ET | 100 | 2.25 |
11:36 ET | 3609 | 2.24 |
11:38 ET | 400 | 2.24 |
11:42 ET | 300 | 2.235 |
11:44 ET | 2200 | 2.23 |
11:45 ET | 915 | 2.22 |
11:47 ET | 4574 | 2.21 |
11:49 ET | 200 | 2.22 |
11:51 ET | 653 | 2.22 |
11:54 ET | 300 | 2.22 |
11:56 ET | 1500 | 2.22 |
12:00 ET | 5400 | 2.215 |
12:02 ET | 500 | 2.22 |
12:03 ET | 11812 | 2.205 |
12:05 ET | 1500 | 2.2 |
12:07 ET | 300 | 2.205 |
12:09 ET | 8197 | 2.22 |
12:12 ET | 800 | 2.22 |
12:14 ET | 1200 | 2.22 |
12:16 ET | 1100 | 2.22 |
12:18 ET | 8087 | 2.2041 |
12:21 ET | 200 | 2.205 |
12:23 ET | 100 | 2.205 |
12:25 ET | 800 | 2.21 |
12:27 ET | 100 | 2.21 |
12:30 ET | 598 | 2.21 |
12:32 ET | 100 | 2.205 |
12:34 ET | 100 | 2.21 |
12:36 ET | 1404 | 2.21 |
12:38 ET | 600 | 2.205 |
12:39 ET | 3827 | 2.21 |
12:41 ET | 500 | 2.21 |
12:43 ET | 500 | 2.21 |
12:45 ET | 11962 | 2.195 |
12:48 ET | 500 | 2.2 |
12:50 ET | 200 | 2.2 |
12:52 ET | 1500 | 2.2 |
12:54 ET | 200 | 2.195 |
12:56 ET | 23910 | 2.1887 |
12:57 ET | 2393 | 2.185 |
12:59 ET | 59744 | 2.18 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Erasca Inc | 552.1M | -2.6x | --- |
Replimune Group Inc | 561.5M | -2.5x | --- |
Cassava Sciences Inc | 565.6M | -9.2x | --- |
Celcuity Inc | 568.3M | -5.8x | --- |
PepGen Inc | 529.0M | -5.1x | --- |
Olema Pharmaceuticals Inc | 582.3M | -5.3x | --- |
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled a wholly owned or controlled RAS/MAPK pathway-focused pipeline in the industry, which is focused on modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes three clinical-stage programs, such as a pan-RAF inhibitor, an ERK inhibitor, and a central nervous system (CNS)-penetrant EGFR inhibitor, and additional discovery-stage programs targeting other key oncogenic drivers. Its lead product candidate is naporafenib, a pan-RAF inhibitor with the potential for patients with NRAS-mutated (NRASm) melanoma, RAS Q61X solid tumors, and other RAS/MAPK pathway-driven tumors.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $552.1M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 238.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.84 |
Book Value | $2.10 |
P/E Ratio | -2.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.